SoFi CEO enters prepaid forward contract on 1.5 million shares
Pyxis Oncology , Inc. (NASDAQ:PYXS) reported the retirement of Pamela Connealy from her roles as Chief Financial Officer and Chief Operating Officer, effective Tuesday. According to a statement based on a filing with the Securities and Exchange Commission, the company indicated that Connealy’s retirement was not the result of any disagreement with the company’s independent auditors or management regarding accounting principles, financial statement disclosure, or internal controls.
In connection with her retirement, Connealy is entitled to severance benefits as outlined in her Amended and Restated Employment Agreement dated November 21, 2022, contingent upon her execution and non-revocation of the company’s standard separation and release agreement. Details regarding her severance benefits are described in Pyxis Oncology’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 29, 2025.
On the same day, Pyxis Oncology appointed Jitendra Wadhane, who previously served as Senior Vice President Finance and Chief Accounting Officer, as the company’s Principal Financial (NASDAQ:PFG) Officer. Wadhane will continue in his role as Principal Accounting Officer and, as of Tuesday, will not receive additional compensation related to his new responsibilities.
Pyxis Oncology is listed on the Nasdaq Global Select Market under the ticker symbol PYXS. The information in this article is based on a press release statement and the company’s recent SEC filing.
In other recent news, Pyxis Oncology, Inc. has reported promising preclinical data for its leading drug candidate, micvotabart pelidotin (MICVO). The studies highlighted MICVO’s potential to disrupt tumor structure and induce immunogenic cell death, showing significant anti-tumor activity across multiple solid tumor indications. This development was presented at the American Association for Cancer Research Annual Meeting, indicating potential benefits for patients with recurrent and metastatic head and neck squamous cell carcinoma and other advanced solid tumors. MICVO has received Fast Track Designation from the U.S. Food and Drug Administration and is being evaluated in Phase 1 clinical trials. Additionally, Pyxis Oncology held its Annual Meeting of Stockholders, where three Class I directors were elected to serve until 2028. The stockholders also ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm. These developments underscore Pyxis Oncology’s ongoing efforts in advancing cancer therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.